drugset / Trial / NCT04167657
SinTilimab After Radiation (STAR Study)
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm multi-center phase II clinical study, which aims to investigate the efficacy and safety of sintilimab after radiotherapy in patients with advanced NSCLC who failed first-line or second-line systemic treatment.
Timeline
- Start
- 2019-04-15
- Primary completion
- 2023-11-30
- Completion
- 2024-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |